Profiling of proteins associated with cisplatin resistance in ovarian cancer cells

International Journal of Gynecological Cancer

Volumn 15, Issue 5, 2005, Pages 747-754

  Zhu, Kun ^a   Fukasawa, I ^a   Fujinoki, M ^a   Furuno, M ^a   Inaba, F ^a   Yamazaki, T ^a   Kamemori, T ^a   Kousaka, N ^a   Ota, Y ^a   Hayashi, M ^b   Maehama, T ^c   Inaba, N ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Cell culture; Cisplatin resistance; Human ovarian cancer cell lines; Protein expression; ProteinChip assay

Indexed keywords

CISPLATIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEIN ARRAY ANALYSIS;

EID: 28944443786     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00247.x     Document Type: Article

References (30)

1. Andrews PA, Velury S, Mann SC, Howell SB. cis-Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988;48:68-73.
2. Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer 1992;66:1109-15.
3. Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 1992;52:6885-9.
4. Kasahara K, Fujiwara Y, Nishio K et al. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 1991;51:3237-42.
5. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988;241:1813-5.
6. Lai GM, Ozols RF, Smyth JF, Young RC, Hamilton TC. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 1988;37:4597-600.
7. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 1988;48:5713-6.
8. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1-6.
9. Dempke W, Voigt W, Grothey A, Hul BT, Schmoll HJ. Cisplatin resistance and oncogenes-a review. Anticancer Drugs 2000;11:225-36.
10. Fung ET, Wright GL Jr, Dalmasso EA. Proteomic strategies for biomarker identification: progress and challenges. Curr Opin Mol Ther 2000;2:643-50.
11. Johnston-Wilson NL, Bouton CM, Pevsner J, Breen JJ, Torrey EF, Yolken RH. Emerging technologies for large-scale screening of human tissues and fluids in the study of severe psychiatric disease. Int J Neuropsychopharmacol 2001;4:83-92.
12. Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000;21:1164-77.
13. Austen BM, Frears ER, Davies H. The use of SELDI ProteinChip™ arrays to monitor production of Alzheimer's β-amyloid in transfected cells. J Peptide Sci 2000;6:459-69.
14. Kohn KW. Molecular interaction map of the mammalian cell cycle control and DNA repair systems. Mol Biol Cell 1999;10:2703-34.
15. Ohndorf UM, Rould MA, He Q, Pabo CO, Lippard SJ. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 1999;399:708-12.
16. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996;271:19645-8.
17. Fink D, Nebel S, Norris PS et al. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer 1998;77:741-6.
18. Fink D, Zheng H, Nebel S et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997;57:1841-5.
19. Ishikawa T, Bao JJ, Yamane Y et al. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 1996;271:14981-8.
20. Mack KM, Canada RG, Andrews PA. The effects of terbium on the cellular accumulation of cisplatin in MDA-MB-231 human breast tumor cells. Cancer Chemother Pharmacol 1997;39:217-22.
21. Chen ZS, Mutoh M, Sumizawa T et al. An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells. Exp Cell Res 1998;240:312-20.
22. Shen D, Pastan I, Gottesman MM. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 1998;58:268-75.
23. Katano K, Kondo A, Safaei R et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002;62:6559-65.
24. Komatsu M, Sumizawa T, Mutoh M et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 2000;60:1312-6.
25. Kanzaki A, Nakayama K, Miyashita H et al. Mutation analysis of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinomas. Anticancer Res 2003;23:1913-5.
26. Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol 2003;64:466-73.
27. Miyashita H, Nitta Y, Mori S et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin. Oral Oncol 2003;39:157-62.
28. Yaneva J, Leuba SH, Van Holde K, Zlatanova J. The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA. Proc Natl Acad Sci USA 1997;94:13448-51.
29. Tsurutani J, Soda H, Oka M et al. Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines. Int J Cancer 2003;104:238-42.
30. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994;54:4313-20.